ISCO — International Stem Cell Income Statement
0.000.00%
Last trade - 00:00- $0.58m
- $2.69m
- $7.79m
- 53
- 65
- 13
- 39
Annual income statement for International Stem Cell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.47 | 7.13 | 7.18 | 8.18 | 7.79 |
| Cost of Revenue | |||||
| Gross Profit | 5.54 | 4.35 | 4.24 | 4.91 | 4.61 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15.2 | 9.95 | 7.96 | 8.36 | 8.45 |
| Operating Profit | -5.73 | -2.82 | -0.784 | -0.183 | -0.663 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.26 | -2.72 | -0.899 | -0.331 | -0.131 |
| Net Income After Taxes | -4.26 | -2.72 | -0.899 | -0.331 | -0.131 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.26 | -2.72 | -0.899 | -0.331 | -0.131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.26 | -2.72 | -0.899 | -0.331 | -0.131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.363 | -0.353 | -0.228 | -0.041 | -0.016 |